Testing Atovaquone for Platinum-Resistant Ovarian Cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether a drug called atovaquone, already used for other conditions, can help people with ovarian cancer that no longer responds to platinum chemotherapy. It aims to find a new treatment option for this hard-to-treat type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have high-grade serous ovarian cancer that stopped responding to platinum chemotherapy and got worse within 6 months of your last treatment.
- You should be generally active and able to care for yourself (ECOG 0 or 1).
- There’s no limit on how many prior treatments you’ve had.
- You must be 18 or older.
- You cannot be pregnant or breastfeeding.
- You must be able to make your own medical decisions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests a new drug, mocertatug rezetecan, against standard treatments for ovarian cancer that no longer responds to platinum chemo. It's for people who have had 1 to 4 prior therapies and may offer a new option if you haven't tried all standard treatments yet.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
This trial tests a combination of two targeted drugs for advanced or recurrent ovarian cancer in people who do not have a BRCA gene change. The goal is to see if the combination can shrink tumors or slow the disease.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial is testing a new drug (SHR-A1811) versus standard chemotherapy for women with platinum-resistant ovarian cancer. The study looks at a specific protein (HER2) to see if the new treatment can help slow or stop the cancer.
Hear when a new Platinum-Resistant Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.